Latest News

  • Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia Read More
  • Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder Read More
  • Alkermes plc Reports Financial Results for the Periods Ended Dec. 31, 2013 and Provides Financial Expectations for 2014 Read More

Investors

Learn More

Working at Alkermes

Join Our Team